MAPS PrEP Van Study
Part of paid clinical trials in Durham, North Carolina.
- Sponsor
- Duke University
- Study ID
- NCT06908252
- Phase
- PHASE4
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Pre-Exposure Prophylaxis (PrEP) — DRUGOral Pre-Exposure Prophylaxis (PrEP) pills
Study Details
For this study the investigators aim to see if giving participants an oral HIV prevention medication on a medical van, is a good option of care for individuals who inject drugs and/or are sexually active and therefore at a higher risk of contracting HIV.
Key Dates
- Start date
- Sep 17, 2025
- Status verified
- Jan 2026
- Primary completion
- Jun 30, 2026
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- PREVENTION
Arms
- Experimental: PrEPAll eligible participants will be given oral PrEP pills to reduce their risk for contracting HIV.
Primary Outcome Measure
Enrollment [ Time Frame: Baseline ]
Central Contacts
- Amelia R Ashkin-Baker, BA(919)448-8680
- Madelene Travis, BA
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Duke Department of Population Health Sciences | Durham | North Carolina | 27701 | Jacqueline Hodges, MD, MPH Jaqueline Hodges, MD, MPH (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Durham, NC
By condition
By specialty
By research site
Related Studies
- Menopausal HT for Women Living With HIV (HoT)PHASE4 · Recruiting · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Birmingham, Alabama
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionPHASE1/PHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · La Jolla, California
- Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility StudyRecruiting · AIDS Malignancy Consortium · La Jolla, California
- Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin LymphomaPHASE1 · Recruiting · AIDS Malignancy Consortium · Duarte, California